One of the companies with which LCFR's owner (Lesmoir-Gordon, Boyle & Co Ltd) is involved is Nanosight, which has developed instruments for analysing nanoparticles.
The Telegraph recently featured Nanosight in an article which can be accessed by clicking here. It provides a fascinating insight into the decisions which emerging game changing businesses face if they are to develop successfully into sizable companies. As the article indicates, further capital may need to be raised depending upon the development path selected - if this does prove to be the case, I would anticipate LCFR bringing the fundraising to the attention of those of its readers who have registered on www.sophisticated-investor.co.uk.
Another article to which I would draw your attention concerns Omega Diagnostics, the subject of one of last week's Stockopedia interviews which can be accessed by clicking here. This is a company which I am an investor in and what I like about the article is that it enables private investors to access the key nuances of the business which come out in institutional investor presentations. The company is a classic illustration of a business with an established platform and very interesting potential but which, with a market cap of £13.5 million, will elicit very limited interest from institutional investors in between fundraisings.
This in turn illustrates both the opportunity for private investors and also the symbiotic roles which private investors (share price formation process) and institutional investors (heavy lifters for fundraisings) need to fulfil to make capital markets function for smallcaps.
Stockopedia is making it much easier for companies to market themselves to both investor audiences, with limited incremental effort required to reach the private investor audience.
